Nelson Vergel
Founder, ExcelMale.com
By Nelson Vergel | B.S. Chemical Engineering, MBA | Founder, ExcelMale.com | 34+ years on TRT | NIH and FDA advisory panel service | Author: Testosterone: A Man's Guide, Beyond Testosterone, The Peptide Consensus
Curated By Nelson Vergel | ExcelMale.com | Updated July 2026
Roughly two thirds of men who start a GLP-1 report a gut symptom of some kind, and a large share of them stop the drug in the first year. Most of those quits are avoidable. They happen because nobody told the patient which symptoms are part of the adjustment and which ones are the body raising a hand.
The ExcelMale forum has covered what GLP-1s do well: the weight loss, the testosterone recovery that follows fat loss, the muscle preservation strategy when you stack one with TRT. This article covers the other half of the conversation. When do you push through, when do you slow down, when do you stop for good, and who should never pick up the pen in the first place.
These symptoms follow a predictable curve. They peak in the week or two after each dose increase, then settle. That pattern is the tell: a symptom that arrives after you titrate up and eases over the following weeks is the drug doing exactly what it does, which is slowing your stomach down.
Red flags do not follow that curve. They arrive out of proportion to the dose, they escalate rather than settle, and they come with signs that a specific organ is in trouble.
The pancreatitis rule deserves emphasis because it is the one place where "wait and see" is wrong. Acute pancreatitis is rare with these drugs, and the causal link is still debated in the literature. But once a case is confirmed and attributed to the medication, the guidance is unambiguous: you do not restart. Not the same drug, not a different one in the class. Men in the forum occasionally ask whether they can switch from semaglutide to tirzepatide after a pancreatitis episode. The answer is no.
That means the fix is not always "stop the drug." A man dropping weight fast on tirzepatide who develops gallstones has a rapid-weight-loss complication, and slowing the rate of loss is a legitimate response alongside surgical consultation. A meta-analysis of tirzepatide trials found the gallbladder and biliary disease signal without a corresponding pancreatitis signal, which supports treating these as two separate problems with two separate decision trees.
Medullary thyroid carcinoma or MEN 2, personal or family history, is the hard line. Every drug in the class carries this contraindication. It comes from rodent C-cell tumor data, and whether it translates to humans remains unproven, but no responsible prescriber works around it. If a first-degree relative has had MTC, you are out.
Confirmed prior drug-associated pancreatitis is the second absolute stop, for the reason covered above.
Beyond those two, the picture is about risk management:
Advanced chronic kidney disease raises the stakes on GI side effects. Vomiting and diarrhea deplete volume, volume depletion cuts renal perfusion, and a kidney with little reserve can tip into acute injury. This does not rule out therapy. It means slower titration, aggressive hydration, and a lower threshold for pausing.
Decompensated cirrhosis is a stop, based on absence of safety data rather than a specific harm signal. Compensated liver disease and fatty liver are a different situation entirely, and GLP-1s often help there.
Type 1 diabetes is not a routine indication. It gets considered case by case in men with obesity, and the DKA risk is real if basal insulin is reduced carelessly.
Established diabetic retinopathy calls for a baseline eye exam and slower titration. The mechanism here is worth understanding, because it is counterintuitive: it is the speed of glycemic improvement that transiently worsens retinopathy, not the drug. Any rapid A1C drop does this. GLP-1s are potent, so they do it more.
Gastroparesis, or a history of it, is a relative contraindication that gets overlooked. You are taking a drug whose primary mechanism is slowing gastric emptying. If your stomach already empties poorly, that is a bad match.
The standard schedules build in four-week steps for a reason. That window gives your gut time to adapt to a slower digestive rhythm before the next increase stacks on top. Escalating faster does not accelerate weight loss in any meaningful way. It accelerates the side effects, which is how men end up quitting in month two.
The schedule is a ceiling, not a quota. Nothing bad happens if you sit at 5 mg of tirzepatide for eight weeks instead of four. Real-world clinic data show that men who titrate slower stay on therapy longer, and staying on therapy is what produces results. The dose you tolerate beats the dose you abandon.
A few behavioral adjustments do most of the work on the symptom side. Eat smaller portions more often instead of three large meals. Put the fork down between bites, because the satiety signal now arrives earlier than you are used to and you will overshoot it if you eat fast. Cut high-fat and fried food, which sits in a slowed stomach the longest and is the most reliable nausea trigger. Sip water constantly rather than gulping it. Ginger helps some men with mild nausea and costs nothing to try.
If you are on oral semaglutide, the administration rules are not optional. Take it fasted, first thing, with about 4 ounces of plain water, and wait a full 30 minutes before food or any other medication. Miss that window and you have taken an expensive placebo.
In June 2023 the American Society of Anesthesiologists recommended holding GLP-1s before elective procedures, one day for daily formulations and one week for weekly ones, because delayed gastric emptying raises the theoretical risk of aspirating stomach contents under sedation. The recommendation was consensus-based rather than evidence-based, and it caused problems: cancelled procedures, worsened glycemic control, and no clear demonstration that it helped.
Then the evidence caught up. Retrospective cohort studies comparing GLP-1 users to non-users largely failed to find the increase in aspiration and postoperative respiratory complications that the guidance assumed. In October 2024, the ASA reversed course and advised that most patients continue their GLP-1 before elective surgery. A multi-society guidance document published in Clinical Gastroenterology and Hepatology, developed with the AGA and several surgical societies, landed in the same place: shared decision-making, individualized risk assessment, and continuation for most patients rather than blanket discontinuation.
What this means for you practically: tell your anesthesiologist and your surgeon that you are on a GLP-1, and tell them the last dose date. Then let them make the call. If you have significant GI symptoms in the run-up to a procedure, that is the situation where holding a dose or extending your liquid fast still makes sense. Do not stop your medication on your own based on a 2023 rule that no longer stands.
Levothyroxine is the one that matters most for the ExcelMale demographic, because thyroid medication and TRT overlap heavily in this population. Delayed gastric emptying alters levothyroxine absorption, and men who have been rock-stable on the same dose for years can drift after starting a GLP-1. Recheck TSH roughly 6 to 8 weeks after starting, and again after each significant dose escalation. Separate the timing of the two medications.
Warfarin and other narrow-therapeutic-index oral drugs deserve closer monitoring for the same reason. A drug where a small change in absorption produces a meaningful change in effect is a drug worth watching.
Insulin and sulfonylureas carry hypoglycemia risk when combined with a GLP-1. On their own, GLP-1s rarely cause hypoglycemia because their insulin effect is glucose-dependent. Add a sulfonylurea and that safety margin disappears. Doses usually need to come down.
Antihypertensives and diuretics intersect with the volume depletion problem. GLP-1s modestly lower blood pressure on their own, and GI fluid losses compound it. If you get lightheaded standing up, that is the mechanism, and your blood pressure medications may need adjusting rather than your GLP-1.
Oral contraceptives matter if a partner is on one. Delayed gastric emptying can reduce absorption enough to compromise efficacy, which is the sort of interaction nobody mentions until it becomes relevant.
The body composition line is the one most men skip and most regret. Scale weight tells you nothing about what you lost. Men on TRT have an advantage here that men not on TRT do not, and pairing resistance training with adequate protein is what converts that advantage into preserved lean mass.
For the other side of this conversation, see the ExcelMale guides on combining TRT with semaglutide and tirzepatide and preventing muscle loss during GLP-1 treatment.
Nelson Vergel is the author of Testosterone: A Man's Guide, Beyond Testosterone, and The Peptide Consensus. For affordable hormone and metabolic lab testing, visit DiscountedLabs.com.
Curated By Nelson Vergel | ExcelMale.com | Updated July 2026
Roughly two thirds of men who start a GLP-1 report a gut symptom of some kind, and a large share of them stop the drug in the first year. Most of those quits are avoidable. They happen because nobody told the patient which symptoms are part of the adjustment and which ones are the body raising a hand.
The ExcelMale forum has covered what GLP-1s do well: the weight loss, the testosterone recovery that follows fat loss, the muscle preservation strategy when you stack one with TRT. This article covers the other half of the conversation. When do you push through, when do you slow down, when do you stop for good, and who should never pick up the pen in the first place.
What GLP-1 Side Effects Are Normal, and Which Ones Mean Stop Immediately?
Almost everything you will feel in the first three months is gastrointestinal, dose-related, and temporary. Nausea is the most common complaint by a wide margin. Constipation, diarrhea, vomiting, reflux, burping, and a heavy full feeling after small meals all show up regularly. In the pooled trial data across the class, nausea runs in the 30 to 45 percent range at higher doses, with vomiting and diarrhea each in the 15 to 35 percent range depending on the agent and the dose.These symptoms follow a predictable curve. They peak in the week or two after each dose increase, then settle. That pattern is the tell: a symptom that arrives after you titrate up and eases over the following weeks is the drug doing exactly what it does, which is slowing your stomach down.
Red flags do not follow that curve. They arrive out of proportion to the dose, they escalate rather than settle, and they come with signs that a specific organ is in trouble.
| Symptom | What it suggests | What to do |
|---|---|---|
| Nausea, early fullness, mild reflux | Expected delayed gastric emptying | Continue; delay the next dose increase by 1-2 weeks |
| Constipation | Slowed intestinal transit | Continue; hydration, fiber, activity; hold escalation until resolved |
| Vomiting or diarrhea, moderate | Dose is ahead of your tolerance | Pause titration or drop back to the last dose you tolerated |
| Severe abdominal pain radiating to the back | Possible pancreatitis | STOP. Same-day evaluation. Lipase and imaging |
| Persistent right upper quadrant pain with fever | Possible gallbladder disease | STOP. Same-day evaluation. Ultrasound |
| Vomiting or diarrhea you cannot keep ahead of | Volume depletion, acute kidney injury risk | STOP. Same-day evaluation. Electrolytes and renal function |
| Dizziness on standing | Orthostatic hypotension from volume loss | Stop, hydrate, check BP; review your antihypertensives |
| Sudden painless vision loss in one eye | Possible NAION | STOP. Emergency ophthalmology evaluation |
The pancreatitis rule deserves emphasis because it is the one place where "wait and see" is wrong. Acute pancreatitis is rare with these drugs, and the causal link is still debated in the literature. But once a case is confirmed and attributed to the medication, the guidance is unambiguous: you do not restart. Not the same drug, not a different one in the class. Men in the forum occasionally ask whether they can switch from semaglutide to tirzepatide after a pancreatitis episode. The answer is no.
Why Does Rapid Weight Loss Itself Cause Gallstones?
This one confuses people, and the distinction is practical rather than academic. GLP-1s reduce gallbladder contractility, which promotes bile stasis. But the larger driver is the weight loss itself. Losing fat quickly, by any mechanism, raises gallstone risk. Surgical weight loss does it too.That means the fix is not always "stop the drug." A man dropping weight fast on tirzepatide who develops gallstones has a rapid-weight-loss complication, and slowing the rate of loss is a legitimate response alongside surgical consultation. A meta-analysis of tirzepatide trials found the gallbladder and biliary disease signal without a corresponding pancreatitis signal, which supports treating these as two separate problems with two separate decision trees.
Who Should Never Take a GLP-1?
Some contraindications are absolute. Others are judgment calls that depend on how well the underlying condition is controlled.Medullary thyroid carcinoma or MEN 2, personal or family history, is the hard line. Every drug in the class carries this contraindication. It comes from rodent C-cell tumor data, and whether it translates to humans remains unproven, but no responsible prescriber works around it. If a first-degree relative has had MTC, you are out.
Confirmed prior drug-associated pancreatitis is the second absolute stop, for the reason covered above.
Beyond those two, the picture is about risk management:
Advanced chronic kidney disease raises the stakes on GI side effects. Vomiting and diarrhea deplete volume, volume depletion cuts renal perfusion, and a kidney with little reserve can tip into acute injury. This does not rule out therapy. It means slower titration, aggressive hydration, and a lower threshold for pausing.
Decompensated cirrhosis is a stop, based on absence of safety data rather than a specific harm signal. Compensated liver disease and fatty liver are a different situation entirely, and GLP-1s often help there.
Type 1 diabetes is not a routine indication. It gets considered case by case in men with obesity, and the DKA risk is real if basal insulin is reduced carelessly.
Established diabetic retinopathy calls for a baseline eye exam and slower titration. The mechanism here is worth understanding, because it is counterintuitive: it is the speed of glycemic improvement that transiently worsens retinopathy, not the drug. Any rapid A1C drop does this. GLP-1s are potent, so they do it more.
Gastroparesis, or a history of it, is a relative contraindication that gets overlooked. You are taking a drug whose primary mechanism is slowing gastric emptying. If your stomach already empties poorly, that is a bad match.
How Does "Low and Slow" Titration Prevent Most of This?
Titration is the single highest-leverage variable you control, and it is the one most men get wrong by rushing.The standard schedules build in four-week steps for a reason. That window gives your gut time to adapt to a slower digestive rhythm before the next increase stacks on top. Escalating faster does not accelerate weight loss in any meaningful way. It accelerates the side effects, which is how men end up quitting in month two.
| Medication | Starting dose | Interval | Progression |
|---|---|---|---|
| Ozempic (semaglutide) | 0.25 mg weekly | 4 weeks | 0.25, 0.5, 1.0, 2.0 mg |
| Wegovy (semaglutide) | 0.25 mg weekly | 4 weeks | 0.25, 0.5, 1.0, 1.7, 2.4 mg |
| Mounjaro / Zepbound (tirzepatide) | 2.5 mg weekly | 4 weeks | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Rybelsus (oral semaglutide) | 3 mg daily | 4 weeks | 3, 7, 14 mg |
| Saxenda (liraglutide) | 0.6 mg daily | 1 week | up to 3.0 mg |
The schedule is a ceiling, not a quota. Nothing bad happens if you sit at 5 mg of tirzepatide for eight weeks instead of four. Real-world clinic data show that men who titrate slower stay on therapy longer, and staying on therapy is what produces results. The dose you tolerate beats the dose you abandon.
A few behavioral adjustments do most of the work on the symptom side. Eat smaller portions more often instead of three large meals. Put the fork down between bites, because the satiety signal now arrives earlier than you are used to and you will overshoot it if you eat fast. Cut high-fat and fried food, which sits in a slowed stomach the longest and is the most reliable nausea trigger. Sip water constantly rather than gulping it. Ginger helps some men with mild nausea and costs nothing to try.
If you are on oral semaglutide, the administration rules are not optional. Take it fasted, first thing, with about 4 ounces of plain water, and wait a full 30 minutes before food or any other medication. Miss that window and you have taken an expensive placebo.
Do You Really Have to Stop Your GLP-1 Before Surgery?
This is where a lot of published advice, including guidance still sitting in clinic handouts, is out of date.In June 2023 the American Society of Anesthesiologists recommended holding GLP-1s before elective procedures, one day for daily formulations and one week for weekly ones, because delayed gastric emptying raises the theoretical risk of aspirating stomach contents under sedation. The recommendation was consensus-based rather than evidence-based, and it caused problems: cancelled procedures, worsened glycemic control, and no clear demonstration that it helped.
Then the evidence caught up. Retrospective cohort studies comparing GLP-1 users to non-users largely failed to find the increase in aspiration and postoperative respiratory complications that the guidance assumed. In October 2024, the ASA reversed course and advised that most patients continue their GLP-1 before elective surgery. A multi-society guidance document published in Clinical Gastroenterology and Hepatology, developed with the AGA and several surgical societies, landed in the same place: shared decision-making, individualized risk assessment, and continuation for most patients rather than blanket discontinuation.
What this means for you practically: tell your anesthesiologist and your surgeon that you are on a GLP-1, and tell them the last dose date. Then let them make the call. If you have significant GI symptoms in the run-up to a procedure, that is the situation where holding a dose or extending your liquid fast still makes sense. Do not stop your medication on your own based on a 2023 rule that no longer stands.
What Drug Interactions and Absorption Problems Should You Watch?
The interaction profile for this class is not about metabolic enzymes. It is almost entirely mechanical: your stomach empties slower, so oral drugs arrive in the intestine on a different schedule.Levothyroxine is the one that matters most for the ExcelMale demographic, because thyroid medication and TRT overlap heavily in this population. Delayed gastric emptying alters levothyroxine absorption, and men who have been rock-stable on the same dose for years can drift after starting a GLP-1. Recheck TSH roughly 6 to 8 weeks after starting, and again after each significant dose escalation. Separate the timing of the two medications.
Warfarin and other narrow-therapeutic-index oral drugs deserve closer monitoring for the same reason. A drug where a small change in absorption produces a meaningful change in effect is a drug worth watching.
Insulin and sulfonylureas carry hypoglycemia risk when combined with a GLP-1. On their own, GLP-1s rarely cause hypoglycemia because their insulin effect is glucose-dependent. Add a sulfonylurea and that safety margin disappears. Doses usually need to come down.
Antihypertensives and diuretics intersect with the volume depletion problem. GLP-1s modestly lower blood pressure on their own, and GI fluid losses compound it. If you get lightheaded standing up, that is the mechanism, and your blood pressure medications may need adjusting rather than your GLP-1.
Oral contraceptives matter if a partner is on one. Delayed gastric emptying can reduce absorption enough to compromise efficacy, which is the sort of interaction nobody mentions until it becomes relevant.
What Should You Monitor While You Are on One?
Baseline first, then follow the trajectory rather than any single value.| Marker | Why | When |
|---|---|---|
| Comprehensive metabolic panel (creatinine, eGFR, electrolytes) | Renal function and volume status; catches the AKI risk early | Baseline, 3 months, then every 6 |
| A1C and fasting glucose | Glycemic response; guides insulin/sulfonylurea reduction | Baseline, 3 months, 6 months |
| TSH | Absorption drift if you take levothyroxine | Baseline, 6-8 weeks after start and after each escalation |
| Lipase | Only if you develop abdominal pain; not routine screening | Symptom-driven |
| Total and free testosterone | Fat loss raises testosterone; your TRT dose may need revisiting | Baseline, then per your usual TRT schedule |
| Body composition (DEXA or bioimpedance) | Distinguishes fat loss from lean mass loss, which the scale cannot | Baseline, 6 months |
The body composition line is the one most men skip and most regret. Scale weight tells you nothing about what you lost. Men on TRT have an advantage here that men not on TRT do not, and pairing resistance training with adequate protein is what converts that advantage into preserved lean mass.
Frequently Asked Questions
Can I restart a GLP-1 after pancreatitis?
No. A confirmed case of drug-associated pancreatitis is a permanent contraindication for the entire class. Switching to a different GLP-1 does not solve the problem, and the risk of a second, potentially worse episode is not worth the weight loss.Is my nausea a reason to quit?
Almost never. Nausea peaks after a dose increase and settles over the following weeks. The correct response is to hold at your current dose until it resolves rather than escalate on schedule, and to adjust how you eat. Quitting over titration-phase nausea is the most common avoidable failure with these drugs.Do I need to stop my GLP-1 before a colonoscopy or surgery?
Probably not, but tell your anesthesiologist. The ASA reversed its 2023 hold recommendation in October 2024 and now advises most patients to continue. The decision is individualized, and active GI symptoms are the situation where holding a dose still makes sense.Will a GLP-1 interfere with my TRT?
Not directly. There is no pharmacological interaction between testosterone and GLP-1 receptor agonists. What changes is your body composition, and losing significant fat mass can shift SHBG, estradiol, and your free testosterone. Recheck your hormone panel after meaningful weight loss rather than assuming your protocol still fits.What if I develop severe constipation?
Hold your dose escalation until it resolves. Increase hydration, add fiber gradually, and move more. Polyethylene glycol is reasonable if those fail. Constipation that becomes severe abdominal pain with vomiting and no bowel movement is a different problem entirely, and that one is an emergency.Conclusion
One thing that gets lost in the safety conversation: the most common way men come to harm on a GLP-1 is not pancreatitis or gallstones or any of the rare events that generate headlines. It is quitting at week six over nausea that would have resolved at week eight, regaining the weight, and losing the testosterone recovery and cardiometabolic benefit that came with the fat loss. The rare risks deserve the vigilance described above. The common risk deserves patience.For the other side of this conversation, see the ExcelMale guides on combining TRT with semaglutide and tirzepatide and preventing muscle loss during GLP-1 treatment.
Related ExcelMale Forum Discussions
- Navigating Gastrointestinal Impacts of GLP-1 Receptor Agonists - Dr. Michael Camilleri of the Mayo Clinic on why titrating slower than the FDA label recommends reduces GI symptoms and improves adherence.
- The Ultimate GLP-1 Guide: Weight Loss, Side Effects and Sarcopenia Risk - Obesity medicine specialist Dr. Spencer Nadolsky on whether the pancreatitis and muscle loss risks are real or overblown, including the NAION vision signal.
- TRT and GLP-1 Medications: What Men Need to Know About Combining Them - The companion article on why TRT helps preserve lean mass during GLP-1-driven weight loss.
- Ozempic and GLP-1 Impact on Sexual Function - Community discussion of the mixed evidence on erectile dysfunction and libido changes with GLP-1 therapy.
- FDA Moves to Permanently Close the Door on Compounded GLP-1s - Regulatory thread on the end of compounded semaglutide, tirzepatide, and liraglutide access.
- Retatrutide: Complete Guide to Dosing, Results, and Side Effects - The triple agonist, including the dysesthesia side effect that separates it from the rest of the class.
- Retatrutide: A Game Changer in Obesity Pharmacotherapy - Member experiences, including men who stopped GLP-1s entirely because of GI intolerance.
- Looking for Retatrutide Experiences - First-hand accounts of GI side effects and appetite changes, including one member who discontinued the class permanently.
- Semaglutide Forum: Game Changer for Weight Loss - Long-running thread covering the pancreatitis and cholelithiasis safety data alongside member outcomes.
- Tirzepatide vs Semaglutide for A1C and Weight Loss - Network meta-analysis discussion, including the higher GI adverse event rate at higher tirzepatide doses.
- Weighing In on GLP-1 Receptor Agonists for People With HIV - Dr. Suman Srinivasa on lean mass loss and sarcopenia risk in a population already vulnerable to it.
Key References
- Ho CN, Ayers AT, Kohn MA, Umpierrez GE, Klonoff DC. Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk. J Endocr Soc. 2025;9(9):bvaf088. DOI: 10.1210/jendso/bvaf088
- Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol. 2025. DOI: 10.1016/j.cgh.2024.10.003
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. DOI: 10.1001/jama.2023.19574
- Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1214334. DOI: 10.3389/fendo.2023.1214334
- He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Intern Med. 2022;182(5):513-519. DOI: 10.1001/jamainternmed.2022.0338
- Lodhia NA, et al. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management. Am J Gastroenterol. 2024;119(6):1126-1140. DOI: 10.14309/ajg.0000000000002820
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. DOI: 10.1001/jamaophthalmol.2024.2296
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes. 2025. DOI: 10.1038/s41366-025-01859-6
- Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real-world titration, persistence and weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.70004
- Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: SPAQI multidisciplinary consensus statement. Br J Anaesth. 2025. DOI: 10.1016/j.bja.2025.04.001
About ExcelMale
ExcelMale.com is a men's health forum with more than 24,000 members and over 20 years of archived discussion on testosterone replacement therapy, hormone optimization, peptides, sexual health, and metabolic health. Founded by Nelson Vergel - chemical engineer, 34-year TRT patient, and patient advocate with NIH and FDA advisory panel experience - ExcelMale provides evidence-based information that bridges clinical research and real-world patient experience.Nelson Vergel is the author of Testosterone: A Man's Guide, Beyond Testosterone, and The Peptide Consensus. For affordable hormone and metabolic lab testing, visit DiscountedLabs.com.
